Shareholders' (Deficit) Equity (Tables)

Total stock-based compensation expense by type of award was as follows:



		Year Ended
		2015		2014			2013
	(In millions)
SARS		$	1.8	$	(3.2	)	$	9.4
Restricted stock, service based		5.6		4.3			2.3
Restricted stock, performance based		0.1		4.3			2.1
Employee stock purchase plan ("ESPP")		0.3		—			—
Stock options		0.8		0.3			0.3
Total stock-based compensation expense		$	8.6	$	5.7		$	14.1

A summary of the status of the Company’s SARS as of November 30, 2015 and changes during fiscal 2015 is presented below:



	SARS (In millions)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)	Aggregate Intrinsic Value (In millions)
Outstanding at November 30, 2014	1.3		$	10.84
Exercised	(0.4	)	13.24
Canceled	(0.1	)	18.64
Outstanding at November 30, 2015	0.8		$	8.70	2.1	$	7.4
Exercisable at November 30, 2015	0.8		$	8.67	2.1	$	7.3

A summary of the status of the Company’s stock options as of November 30, 2015 and changes during fiscal 2015 is presented below:



	Stock Options (In millions)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)	Intrinsic Value (In millions)
Outstanding at November 30, 2014	0.7		$	6.64
Granted	0.2		23.04
Exercised	(0.2	)	4.88
Canceled	(0.1	)	22.38
Outstanding at November 30, 2015	0.6		$	12.29	3.8	$	4.4
Exercisable at November 30, 2015	0.4		$	7.50	2.7	$	4.4
Expected to vest at November 30, 2015	0.2		$	23.02	6.3	$	—

The following table summarizes the range of exercise prices and weighted-average exercise prices for options outstanding as of November 30, 2015 under the Company’s stock option plans:



		Outstanding
Year Granted	Range of Exercise Prices	Stock Options Outstanding (In millions)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)
2009	$4.54	0.1	$	4.54	3.6
2010	$4.91 - $7.14	0.1	$	6.13	1.5
2011	$6.01	0.1	$	6.01	2.3
2014	$16.59 - $17.27	0.1	$	17.03	5.3
2015	$20.48 - $23.06	0.2	$	23.02	6.3
		0.6

The following is summary of the status of the Company’s service-based restricted stock as of November 30, 2015 and changes during fiscal 2015:



	Service Based Restricted Stock (In millions)		Weighted Average Grant Date Fair Value
Outstanding at November 30, 2014	0.7		$	13.80
Granted	0.2		20.70
Vested	(0.3	)	20.90
Canceled	(0.1	)	16.94
Outstanding at November 30, 2015	0.5		$	18.22
Expected to vest at November 30, 2015	0.4		$	18.23

The following is a summary of the status of the Company’s performance-based restricted stock as of November 30, 2015 and changes during fiscal 2015:



	Performance Based Restricted Stock (In millions)		Weighted Average Grant Date Fair Value
Outstanding at November 30, 2014	1.2		$	14.67
Granted	0.6		21.33
Vested	(0.4	)	17.69
Canceled	(0.4	)	18.63
Outstanding at November 30, 2015	1.0		$	18.89
Expected to vest at November 30, 2015	0.4		$	19.09

The fair value of stock options was estimated using a Black-Scholes Model with the following weighted average assumptions:



	Year Ended
	2015		2014
Expected life (in years)	7.0		7.0
Volatility	58.06	%	58.92	%
Risk-free interest rate	1.94	%	2.27	%

The fair value of SARS was estimated using a Black-Scholes Model with the following weighted average assumptions:



	Year Ended
	2015		2014		2013
Expected life (in years)	2.1		2.6		3.6
Volatility	34.00	%	28.00	%	44.3	%
Risk-free interest rate	0.94	%	0.75	%	0.84	%